Document is current
Any future updates will be listed below
-
Authors
Doppler, Christian
Feischl, Michael
Ganhör, Clara
Puh, Spela
Müller, Marina
Kotnik, Michaela
Mimler, Teresa
Sonnleitner, Max
Bernhard, David
Wechselberger, Christian
-
Funding
Funding for this research was provided by:
MED-CALL program of the Medical Faculty, Johannes Kepler University Linz
Österreichische Forschungsförderungsgesellschaft (FFG 880919)
Johannes Kepler University Linz
- License Information
-
More Information
Article History
Received: 13 December 2021
Revised: 28 January 2022
Accepted: 7 February 2022
First Online: 28 February 2022
Declarations
:
: The authors state that they have obtained appropriate institutional review board approval (see the “InternalRef removed” section).
: All authors have read and approved the manuscript for publication.
: C. Wechselberger has been an employee of Greiner Bio-One Diagnostics GmbH from 2009 – 2016. During this time, he was member of the project team that developed the Genspeed assay platform. Since then C. Wechselberger had no professional affiliation with Genspeed Biotech GmbH. The Division of Pathophysiology is serving as a reference laboratory for Genspeed Biotech GmbH within the Emergency-Call COVID-19 (Österreichische Forschungsförderungsgesellschaft mbH FFG 880919). M. Sonnleitner is heading the development of the Genspeed assay platform and currently serves as CEO for Genspeed Biotech GmbH. All other authors declare no competing interests.
